CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acesis Holdings Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acesis Holdings Corp
9233 Park Meadows Rive, Suite 108
Phone: (720) 389-0650p:720 389-0650 LONE TREE, CO  80124  United States
Business Summary
Acesis Holdings Corp is a United States-based company. The Company operates as pre-phase I (first-in-man (FIM) clinical, biotechnology company focused on men’s health. The Company develops treatments for low testosterone levels in males (Low-T) known as T-deficiency or male hypogonadism. Its business model is to develop non-steroid product candidates that transform the treatment of men with Low-T. The Company’s lead peptide, ACE-167, has been designed to act through a molecular mechanism to induce the Leydig cells of the testis to synthesize testosterone thereby restoring endogenous T production. The attributes of ACE-167, including its mechanism of action and non-steroidal composition. The Company’s wholly owned subsidiaries include Acesis Biomed Limited and Acesis Biomed US, Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director KonstantinosKaratzas 64
Chief Financial Officer, Treasurer Duane C.Knight 62
Chief Operating Officer, Corporate Secretary Thomas B.Olson 57
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ACESIS BIOMED LTD SUITE 1 15 INGESTRE PLACE LONDON LONDON United Kingdom

Business Names
Business Name
Acesis Biomed Ltd.
Acesis Biomed US Inc.

General Information
Outstanding Shares: 16,122,270 (As of 6/30/2023)
Federal Tax Id: 884251528


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024